Solveig Linko

Solveig Linko

Auto-generated profile, based on publicly available information

Solveig Linko

Linko Q-Solutions , Helsinki , Finland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
FVFlorent J. L. A. Vanstapel
Florent J. L. A. Vanstapel
MOMatthias Orth
Matthias Orth
TSThomas Streichert
Thomas Streichert
ETTORE CAPOLUONGOETTORE CAPOLUONGO
ETTORE CAPOLUONGO
WOWytze P. Oosterhuis
Wytze P. Oosterhuis
MNMichael Neumaier
Michael Neumaier
The EU In-Vitro Diagnostic Device Regulation (IVDR) aims for transparent risk-and purpose-based validation of diagnostic devices, traceability of results to uniquely identified devices, and post-market surveillance. The IVDR regulates design, manufacture and putting into use of devices, but not medical services using these devices. In the absence of suitable commercial devices, the laboratory can resort to laboratory-developed tests (LDT) for in-house use. Documentary obligations (IVDR Art 5.5), the performance and safety specifications of ANNEX I, and development and manufacture under an ISO 15189-equivalent quality system apply. LDTs serve specific clinical needs, often for low volume niche applications, or correspond to the translational phase of new tests and treatments, often extremely relevant for patient care. As some commercial tests may disappear with the IVDR roll-out, many will require urgent LDT replacement. The workload will also depend on which modifications to commercial tests turns them into an LDT, and on how national legislators and competent authorities (CA) will handle new competences and responsibilities. We discuss appropriate interpretation of ISO 15189 to cover IVDR requirements. Selected cases illustrate LDT implementation covering medical needs with commensurate management of risk emanating from intended use and/or design of devices. Unintended collateral damage of the IVDR comprises loss of non-profitable niche applications, increases of costs and wasted resources, and migration of innovative research to more cost-efficient environments. Taking into account local specifics, the legislative framework should reduce the burden on and associated opportunity costs for the health care system, by making diligent use of existing frameworks.

28 May 2025 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
HÇHikmet Can Can Çubukçu
Hikmet Can Can Çubukçu
GBGuilaine Boursier
Guilaine Boursier
SLSolveig Linko
Solveig Linko
FAFRANCISCO ANTONIO BERNABEU ANDREU
FRANCISCO ANTONIO BERNABEU ANDREU
PBPika Meško Brguljan
Pika Meško Brguljan
OAon behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Division: Quality, Standards and Regulations, Committee on Accreditation and ISO/CEN standards (C: A/ISO)
on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Division: Quality, Standards and Regulations, Committee on Accreditation and ISO/CEN standards (C: A/ISO)
Artificial intelligence (AI) is rapidly transforming laboratory medicine, impacting medical devices and healthcare practices. Despite these advancements, AI-based medical device software (MDSW) introduces a new layer of complexity in regulatory compliance. This paper outlines the regulatory landscape for MDSW and AI-driven MDSW, clarifying the responsibilities of laboratory professionals and manufacturers under the In Vitro Diagnostic Regulation (IVDR), ISO 15189:2022, and the Artificial Intelligence Act. An analysis of 89 MDSWs approved under the IVDR, derived from the European Database on Medical Devices (EUDAMED) reveals a diverse landscape of applications, ranging from digital pathology and molecular diagnostics to laboratory automation and clinical decision support. While Germany currently dominates the EU market for these devices, and the majority of approved MDSW remain non-AI driven and classified as low-risk, the increasing presence of AI-powered Class C devices underscores the growing potential of software in complex diagnostic scenarios. However, realizing the full potential of AI in laboratory medicine requires careful navigation of the evolving regulatory landscape. Key challenges persist, including defining intended use, ensuring robust clinical evidence, mitigating data bias, and establishing rigorous post-market surveillance. Balancing regulatory oversight with innovation is critical to fostering the development of trustworthy AI systems without stifling progress. As regulatory frameworks continue to evolve, establishing clear validation methodologies and transparent compliance pathways will be essential to unlocking the full potential of AI in laboratory medicine while ensuring the highest standards of safety and clinical effectiveness.

19 October 2023 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
HÇHikmet Can Can Çubukçu
Hikmet Can Can Çubukçu
FVFlorent Vanstapel
Florent Vanstapel
MTMarc Thelen
Marc Thelen
MLMarith van Schrojenstein Lantman
Marith van Schrojenstein Lantman
FAFRANCISCO ANTONIO BERNABEU ANDREU
FRANCISCO ANTONIO BERNABEU ANDREU
GBGuilaine Boursier
Guilaine Boursier
Objectives: According to ISO 15189:2022, analytical performance specifications (APS) should relate to intended clinical use and impact on patient care. Therefore, we aimed to develop a web application for laboratory professionals to calculate APS based on a simulation of the impact of measurement uncertainty (MU) on the outcome using the chosen decision limits, agreement thresholds, and data of the population of interest. Methods: We developed the “APS Calculator” allowing users to upload and select data of concern, specify decision limits and agreement thresholds, and conduct simulations to determine APS for MU. The simulation involved categorizing original measurand concentrations, generating measured (simulated) results by introducing different degrees of MU, and recategorizing measured concentrations based on clinical decision limits and acceptable clinical misclassification rates. The agreements between original and simulated result categories were assessed, and values that met or exceeded user-specified agreement thresholds that set goals for the between-category agreement were considered acceptable. The application generates contour plots of agreement rates and corresponding MU values. We tested the application using National Health and Nutrition Examination Survey data, with decision limits from relevant guidelines. Results: We determined APS for MU of six measurands (blood total hemoglobin, plasma fasting glucose, serum total and high-density lipoprotein cholesterol, triglycerides, and total folate) to demonstrate the potential of the application to generate APS. Conclusions: The developed data-driven web application offers a flexible tool for laboratory professionals to calculate APS for MU using their chosen decision limits and agreement thresholds, and the data of the population of interest.

12 November 2019 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Open access
PDF file
RBRoseri Roelofsen-De Beer
Roseri Roelofsen-De Beer
JWJos Wielders
Jos Wielders
GBGuilaine Boursier
Guilaine Boursier
TVTatjana Vodnik
Tatjana Vodnik
FVFlorent Vanstapel
Florent Vanstapel
MTMarc Thelen
Marc Thelen
This paper reflects the opinion of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group Accreditation and ISO/CEN standards (WG-A/ISO). It aims to provide guidance for drawing up local/national documents about validation and verification of laboratory methods. We demonstrate how risk evaluation can be used to optimize laboratory policies to meet intended use requirements as well as requirements of standards. This is translated in a number of recommendations on how to introduce risk evaluation in various stages of the implementation of new methods ultimately covering the whole process cycle.

6 January 2025 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
SLSolveig Linko
Solveig Linko
GBGuilaine Boursier
Guilaine Boursier
FBFrancisco A. Bernabeu-Andreu
Francisco A. Bernabeu-Andreu
NDNana Dzneladze
Nana Dzneladze
FVFlorent Vanstapel
Florent Vanstapel
MTMarc Thelen
Marc Thelen
The EN ISO 15189:2022 standard, titled “Medical laboratories – Requirements for quality and competence,” is a significant update to the regulations for medical laboratories. The revised standard was published on December 6, 2022, replacing both EN ISO 15189:2012 and EN ISO 22870:2016. Key objectives of the revision include: 1. Alignment with ISO/IEC 17025:2017, 2. Removal of unintended prescription, 3. Focus on patient interest and safety, 4. Minimization of new requirements, and 5. Improved clarity of text. Dedicating to harmonizing accreditation processes across Europe the EFLM Committee on Accreditation and ISO/CEN standards (C: A/ISO) has produced this guidance document to assist the laboratory medicine community in understanding and implementing the criteria of the EN ISO 15189 revision. Two main objectives of the guidance in educating both laboratories and accreditation bodies with their assessors as well as other stakeholders in laboratory medicine were agreed on. Firstly, to clarify the relevant changes covering all paragraphs of the standard and secondly to make an impact analysis on previous C: A/ISO guidance documents.

4 December 2018 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
PDF file
MTMarc Thelen
Marc Thelen
FVFlorent Vanstapel
Florent Vanstapel
PBPika Meško Brguljan
Pika Meško Brguljan
BGBernard Gouget
Bernard Gouget
GBGuilaine Boursier
Guilaine Boursier
NNNull Null
Null Null
ISO15189:2012 requires medical laboratories to document metrological traceability of their results. While the ISO17511:2003 standard on metrological traceability in laboratory medicine requires the use of the highest available level in the traceability chain, it recognizes that for many measurands there is no reference above the manufacturer’s selected measurement procedure and the manufacturer’s working calibrator. Some immunoassays, although they intend to measure the same quantity and may even refer to the same reference material, unfortunately produce different results because of differences in analytical selectivity as manufacturers select different epitopes and antibodies for the same analyte. In other cases, the cause is the use of reference materials, which are not commutable. The uncertainty associated with the result is another important aspect in metrological traceability implementation. As the measurement uncertainty on the clinical samples is influenced by the uncertainty of all steps higher in the traceability chain, laboratories should be provided with adequate and appropriate information on the uncertainty of the value assignment to the commercial calibrators that they use. Although the between-lot variation in value assignment will manifest itself as part of the long-term imprecision as estimated by the end-user, information on worst-case to be expected lot-lot variation has to be communicated to the end-user by the IVD provider. When laboratories use ancillary equipment that potentially could have a critical contribution to the reported results, such equipment needs verification of its proper calibration and criticality to the result uncertainty could be assessed by an approach based on risk analysis, which is a key element of ISO15189:2012 anyway. This paper discusses how the requirement for metrological traceability as stated in ISO15189 should be met by the medical laboratory and how this should be assessed by accreditation bodies.